- Thalidomide epidemics - 50 years after2012 | First Faculty of Medicine, Third Faculty of Medicine
- Thalidomide as an immunomodulatory agent1999 | Faculty of Pharmacy in Hradec Králové
- Thalidomide +12005 | Faculty of Medicine in Hradec Králové
- Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma2010 | First Faculty of Medicine
- Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment2007 | Publication without faculty affiliation
- Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment2007 | First Faculty of Medicine
- Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma2009 | First Faculty of Medicine
- Impact of immunomodulatory drugs in treatment of primary myelofibrosis2015 | Faculty of Medicine in Hradec Králové
- Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment +12007 | Faculty of Medicine in Hradec Králové
- Thalidomid2007 | First Faculty of Medicine
- Low-dose thalidomid in refractory and relapsing multiple myeloma2007 | First Faculty of Medicine
- Successful treatment of anemia and trombocytopenia with Thalidomide and Prednison in idiopatic myelofibrosis2006 | Publication without faculty affiliation
- Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma2011 | First Faculty of Medicine
- Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group2013 | Central Library of Charles University
- Thalidomid +12007 | Faculty of Medicine in Hradec Králové
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.2008 | First Faculty of Medicine
- Nízkodávkovaný Thalidomid v léčbě refrakterního a relabujícího mnohočetného myelomuPublication without faculty affiliation
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- An overview of recent possibilities in pharmacotherapy of diseases of the oral mucosa, salivary glands, and periodontal tissue2013 | Faculty of Medicine in Hradec Králové
- Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration2010 | First Faculty of Medicine
- Embryotoxicity in chick embryo of thalidomide hydrolysis products following metabolic activation by rat liver homogenate1994 | Third Faculty of Medicine
- Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple MyelomaPublication without faculty affiliation
- Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up2015 | First Faculty of Medicine
- Low-dose thalidomid in refractory and relapsing multiple myeloma +12007 | Faculty of Medicine in Hradec Králové
- Integrative role of the SALL4 gene: From thalidomide embryopathy to genetic defects of the upper limb, internal organs, cerebral midline, and pituitary2024 | Second Faculty of Medicine